Changchun high-tech subsidiary gets nod for GenSci140 cancer drug trial

Changchun High & New Technology Industry Group announced that its subsidiary, GeneScience Pharmaceuticals, has received acceptance for its clinical trial application for the domestically manufactured investigational new drug, GenSci140 for injection. The National Medical Products Administration issued the acceptance notice for the clinical trial application. The drug is intended for the treatment of advanced solid tumors.

GenSci140 is a novel bispecific antibody-drug conjugate targeting the folate receptor alpha (FRα/FOLR1) subtype. Developed independently by GeneScience Pharmaceuticals, it utilizes a cleavable linker and carries a topoisomerase I inhibitor payload. Preclinical studies indicate that GenSci140 demonstrates strong anti-tumor effects across various CDX and PDX models, particularly in FRα-positive tumors.

The company anticipates that successful clinical trial progression will broaden its business scope, optimize its product portfolio, and enhance its core competitiveness. However, the company also cautioned investors about the inherent risks associated with pharmaceutical R&D, including the lengthy and complex development cycle and the potential for uncertainties in the clinical trial process.